BRAND NAMES
- Agispor (Israel) shampoo pi, cream PI
- Azolmen, Canesten Unidie (Italy)
- Canespor (Bulgaria)
- Canesten bifonazol (Austria)
- Canesten Extra (Germany)
- Mycospor (Australia patient information, Bulgaria, Bahamas, Barbados, Bermuda, Brazil, Cayman Islands, China, Czech Republic, Georgia, Germany, Greece, Hungary, India, Indonesia, Jamaica, Japan, Mexico, Netherlands, Oman, Peru, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Taiwan, Turkey)
 MECHANISM OF ACTION
Bifonazole is an antifungal agent of the imidazole class. It inhibits lanosterol 14α-demethylase, a cytochrome P-450 enzyme that converts lanosterol to ergosterol.
Ergosterol is an essential component of the fungal cell membrane. The inhibition of its synthesis results in accumulation of toxic 14α-methylated sterols and the production of a defective cell membrane with altered permeability and leakage of cellular contents.
Bifonazole penetrates the skin better than other imidazole derivatives (ketoconazole , clotrimazole), maintaining a high concentration for 48-72 hours.
Bifonazole cream is a topical antifungal cream used to treat skin infections such as tinea, Athlete's foot, jock itch, ringworm of the body, and other skin infections caused by fungi or yeasts.
Apply once a day, at best before retiring. It should be applied thinly to the affected skin area and rubbed in.
The duration of treatment is 2 to 4 weeks depending on the type of infection and site involved.
Hypersensitivity to bifonazole.
Patients with a history of hypersensitivity reactions to other imidazole antifungal agents (e.g. econazole, clotrimazole, miconazole) must use bifonazole containing products with caution.
 PREGNANCY AND LACTATION
In the first 3 months of pregnancy bifonazole should only be used after risk:benefit evaluation by a doctor. Two cases of newborns with severe limb defects who were exposed to high doses of oral (an unacceptable route) and/or intravaginal bifonazole during the entire first trimester of pregnancy were described. Although only two cases are insufficient to establish a relationship, the data suggest that maternal intake of bifonazole in early pregnancy poses a risk of morphogenic malformations.
Bifonazole should only be used in breast-feeding woman after risk:benefit ratio evaluation by a doctor. During lactation period bifonazole should not be applied in the chest area.
 SIDE EFFECTS
Occasionally, skin reactions such as redness, burning, itching, irritation and peeling may occur. These side effects are reversible after discontinuation of the treatment
 RELATED LINKS
|Ergosterol target : Cell membrane target||Azoles (lanosterol 14 alpha-demethylase inhibitors) : Ergosterol inhibitors||Imidazoles||Topical: Bifonazole • Clotrimazole • Econazole • Fenticonazole • Ketoconazole • Isoconazole • Miconazole • Sertaconazole • Tioconazole|
|Triazoles|| Topical: Fluconazole • Terconazole|
Systemic: Fluconazole • Itraconazole • Posaconazole • Voriconazole
|Polyene antimycotics (ergosterol binding; they form pores in the membrane)|| Topical: Nystatin |
Systemic: Amphotericin B
|Allylamines (squalene epoxidase inhibitors) : Ergosterol inhibitors|| Topical: Amorolfine • Naftifine • Terbinafine |
|Echinocandins (β-glucan synthase inhibitors) : Cell wall target||Anidulafungin • Caspofungin • Micafungin|
|Pyrimidine analogues / Thymidylate synthase inhibitors : Nucleic acid inhibitors||Flucytosine|